Technology & Engineering

Research

The Latest

UC San Diego Engineer Andrew Kahng Awarded Ho-Am Prize

University of California San Diego Jacobs School of Engineering Professor Andrew B. Kahng has been awarded the 2019 Ho-Am Prize for Engineering, the highest award for engineering in Korea.

Waiting with Ablated Breath: Is This the Cure for Ventricular Fibrillation?

Patients who suffer from VF live in constant fear of triggering a cardiac event, which can only be treated with an automated external defibrillator and which can become fatal in mere seconds. But a new procedure developed at UC San Diego Health is now presenting an alternative: a curative procedure.

Genome-Wide Analysis Reveals New Strategies to Target Pancreatic Cancer

An international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies – and thus vulnerabilities – of pancreatic cancer stem cells.

Computer Science Professor Rajesh Gupta Receives One of Computing’s Most Prestigious Honors

Rajesh Gupta, a professor of computer science and engineering at University of California San Diego, has been awarded the IEEE Computer Society 2019 W. Wallace McDowell Award for his “seminal contributions in design and implementation of microelectronic systems-on-chip and cyberphysical systems.”

Supercomputers Aid Our Understanding of Complex Brain Waves

Using the Comet supercomputer at the San Diego Supercomputer Center (SDSC) at UC San Diego, campus researchers have demonstrated they can efficiently analyze more than 1,000 EEG 128-channel high-density data sets via the new Open EEGLAB Portal running on SDSC’s Neuroscience Gateway.

UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells

Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.